The sale is de minimis for a director and likely routine portfolio management. Monitor for any larger insider sales or changes in director holdings in future filings.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $299.00entry
- T+1 · 11d ago +2.41%α +2.10% · $306.20
- T+5 · 5d ago +5.78%α +2.49% · $316.27
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Director Jason Aryeh filed a Form 144 on November 4, 2026, indicating intent to sell 282 shares of Class B common stock, with an approximate market value of $90,225.50 based on the filing date price. The shares were acquired in 2019 via secondary market purchases. This is a very small sale relative to the company's $6.1B market cap and the insider's apparent holdings, and carries minimal signal.
Key Facts
- Insider: Jason Aryeh, Director of Ligand Pharmaceuticals
- Shares to be sold: 282 shares of Class B common stock
- Approximate value: $90,225.50 (based on filing date price of ~$320/share)
- Shares acquired: between May 14, 2019 and July 30, 2019 via secondary market purchase
- Broker: Wells Fargo Clearing Services
- Sale intended on or after November 4, 2026 on Nasdaq
- Insider also reported additional holdings acquired on Oct 30, 2026 (1,209 shares) and Nov 2, 2026 (700 shares), total recent acquisitions ~2,111 shares
Financial Impact
Proposed sale of 282 shares worth ~$90K, representing less than 0.002% of market cap
Risk Factors
- Form 144 is only an intent to sell; the sale may not occur
- No material risk to shareholders from this small proposed sale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001957799-26-000193 |
| Document: 0001957799-26-000193-index.html | 0001957799-26-000193 |
| Document: 0001957799-26-000193.txt | 0001957799-26-000193 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Viewing Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers